| abstract |
The present invention in one embodiment is directed to sustained-release dosage forms of cabergoline and other ergoline derivatives, which provide a zero-order or near zero-order release profile. The invention in another embodiment is directed to a method for treating Parkinson's disease, Progressive Supranuclear Palsy, Multisystemic Atrophy, Restless Legs Syndrome, Fibromyalgia, Chronic Fatigue Syndrome, stroke and nervous system disorders, including addictive disorders, using sustained-release dosage forms containing cabergoline or a pharmaceutically acceptable salts thereof. |